{"entity":{"type":"insider","cik":"0001783165","url":"/insider/0001783165","json_url":"/insider/0001783165.json","name":"Adjuvant Global Health Technology Fund, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":22,"n_filings":9,"first":"2022-03-31","last":"2024-01-18","span_basis":"filed_date"},"name_variants":[{"name":"Adjuvant Global Health Technology Fund, L.P.","source":"filing","n_filings":9,"first_seen":"2022-03-31","last_seen":"2024-01-18"}],"transactions":[{"id":2766806,"accession":"0000950170-24-005513","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-005513","line_url":"/filing/0000950170-24-005513","is_derivative":false,"issuer_cik":"0001783165","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001783165","owner_cik":null,"owner_name":"Adjuvant Capital GP, L.P.; Adjuvant Capital Management, LLC; Adjuvant Global Health Technology Fund DE, L.P.; Adjuvant Global Health Technology Fund, L.P.","owner_display_name":"Adjuvant Capital GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":19.65,"price_display":"19.65","price_state":"stated","total_value":1965000.0,"total_display":"1,965,000.00","total_whole":"1,965,000","shares_owned_after":1995958.0,"shares_owned_after_display":"1,995,958","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-16","filed_date":"2024-01-18","scope":"insider","n_lines":2},{"id":8724360,"accession":"0000950170-23-064611","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-23-064611","line_url":"/filing/0000950170-23-064611","is_derivative":false,"issuer_cik":"0001783165","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001783165","owner_cik":null,"owner_name":"Adjuvant Capital GP, L.P.; Adjuvant Capital Management, LLC; Adjuvant Global Health Technology Fund DE, L.P.; Adjuvant Global Health Technology Fund, L.P.","owner_display_name":"Adjuvant Capital GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1810.0,"shares_display":"1,810","price_per_share":16.146,"price_display":"16.15","price_state":"stated","total_value":29224.26,"total_display":"29,224.26","total_whole":"29,224","shares_owned_after":2080051.0,"shares_owned_after_display":"2,080,051","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-14","filed_date":"2023-11-16","scope":"insider","n_lines":2},{"id":7919611,"accession":"0000950170-23-051728","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-23-051728","line_url":"/filing/0000950170-23-051728","is_derivative":false,"issuer_cik":"0001783165","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001783165","owner_cik":null,"owner_name":"Adjuvant Capital GP, L.P.; Adjuvant Capital Management, LLC; Adjuvant Global Health Technology Fund DE, L.P.; Adjuvant Global Health Technology Fund, L.P.","owner_display_name":"Adjuvant Capital GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5672.0,"shares_display":"5,672","price_per_share":16.07,"price_display":"16.07","price_state":"stated","total_value":91149.04,"total_display":"91,149.04","total_whole":"91,149","shares_owned_after":2081573.0,"shares_owned_after_display":"2,081,573","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-10-02","filed_date":"2023-10-03","scope":"insider","n_lines":2},{"id":7919607,"accession":"0000950170-23-051728","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-23-051728","line_url":"/filing/0000950170-23-051728","is_derivative":false,"issuer_cik":"0001783165","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001783165","owner_cik":null,"owner_name":"Adjuvant Capital GP, L.P.; Adjuvant Capital Management, LLC; Adjuvant Global Health Technology Fund DE, L.P.; Adjuvant Global Health Technology Fund, L.P.","owner_display_name":"Adjuvant Capital GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":99101.0,"shares_display":"99,101","price_per_share":16.28,"price_display":"16.28","price_state":"stated","total_value":1613364.28,"total_display":"1,613,364.28","total_whole":"1,613,364","shares_owned_after":2086343.0,"shares_owned_after_display":"2,086,343","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-29","filed_date":"2023-10-03","scope":"insider","n_lines":2},{"id":8599628,"accession":"0000950170-23-050853","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-23-050853","line_url":"/filing/0000950170-23-050853","is_derivative":false,"issuer_cik":"0001783165","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001783165","owner_cik":null,"owner_name":"Adjuvant Capital GP, L.P.; Adjuvant Capital Management, LLC; Adjuvant Global Health Technology Fund DE, L.P.; Adjuvant Global Health Technology Fund, L.P.","owner_display_name":"Adjuvant Capital GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8516.0,"shares_display":"8,516","price_per_share":16.11,"price_display":"16.11","price_state":"stated","total_value":137192.76,"total_display":"137,192.76","total_whole":"137,193","shares_owned_after":2169680.0,"shares_owned_after_display":"2,169,680","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-28","filed_date":"2023-09-29","scope":"insider","n_lines":2},{"id":8599624,"accession":"0000950170-23-050853","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-23-050853","line_url":"/filing/0000950170-23-050853","is_derivative":false,"issuer_cik":"0001783165","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001783165","owner_cik":null,"owner_name":"Adjuvant Capital GP, L.P.; Adjuvant Capital Management, LLC; Adjuvant Global Health Technology Fund DE, L.P.; Adjuvant Global Health Technology Fund, L.P.","owner_display_name":"Adjuvant Capital GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":841.0,"shares_display":"841","price_per_share":16.07,"price_display":"16.07","price_state":"stated","total_value":13514.87,"total_display":"13,514.87","total_whole":"13,515","shares_owned_after":2176840.0,"shares_owned_after_display":"2,176,840","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-27","filed_date":"2023-09-29","scope":"insider","n_lines":2},{"id":8310841,"accession":"0000950170-23-048422","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-23-048422","line_url":"/filing/0000950170-23-048422","is_derivative":false,"issuer_cik":"0001783165","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001783165","owner_cik":null,"owner_name":"Adjuvant Capital GP, L.P.; Adjuvant Capital Management, LLC; Adjuvant Global Health Technology Fund DE, L.P.; Adjuvant Global Health Technology Fund, L.P.","owner_display_name":"Adjuvant Capital GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":6400.0,"total_display":"6,400.00","total_whole":"6,400","shares_owned_after":2177547.0,"shares_owned_after_display":"2,177,547","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-13","filed_date":"2023-09-15","scope":"insider","n_lines":2},{"id":8011922,"accession":"0000950170-23-047312","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-23-047312","line_url":"/filing/0000950170-23-047312","is_derivative":false,"issuer_cik":"0001783165","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001783165","owner_cik":null,"owner_name":"Adjuvant Capital GP, L.P.; Adjuvant Capital Management, LLC; Adjuvant Global Health Technology Fund DE, L.P.; Adjuvant Global Health Technology Fund, L.P.","owner_display_name":"Adjuvant Capital GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3378.0,"shares_display":"3,378","price_per_share":16.05,"price_display":"16.05","price_state":"stated","total_value":54216.9,"total_display":"54,216.90","total_whole":"54,217","shares_owned_after":2177883.0,"shares_owned_after_display":"2,177,883","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-07","filed_date":"2023-09-08","scope":"insider","n_lines":2},{"id":8011918,"accession":"0000950170-23-047312","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-23-047312","line_url":"/filing/0000950170-23-047312","is_derivative":false,"issuer_cik":"0001783165","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001783165","owner_cik":null,"owner_name":"Adjuvant Capital GP, L.P.; Adjuvant Capital Management, LLC; Adjuvant Global Health Technology Fund DE, L.P.; Adjuvant Global Health Technology Fund, L.P.","owner_display_name":"Adjuvant Capital GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3762.0,"shares_display":"3,762","price_per_share":16.02,"price_display":"16.02","price_state":"stated","total_value":60267.24,"total_display":"60,267.24","total_whole":"60,267","shares_owned_after":2180724.0,"shares_owned_after_display":"2,180,724","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-06","filed_date":"2023-09-08","scope":"insider","n_lines":2},{"id":8465253,"accession":"0000950170-23-044594","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-23-044594","line_url":"/filing/0000950170-23-044594","is_derivative":false,"issuer_cik":"0001783165","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001783165","owner_cik":null,"owner_name":"Adjuvant Capital GP, L.P.; Adjuvant Capital Management, LLC; Adjuvant Global Health Technology Fund DE, L.P.; Adjuvant Global Health Technology Fund, L.P.","owner_display_name":"Adjuvant Capital GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":6400.0,"total_display":"6,400.00","total_whole":"6,400","shares_owned_after":2183888.0,"shares_owned_after_display":"2,183,888","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-23","filed_date":"2023-08-25","scope":"insider","n_lines":2},{"id":9205254,"accession":"0000899243-22-024034","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-024034","line_url":"/filing/0000899243-22-024034#line-1","is_derivative":false,"issuer_cik":"0001783165","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001783165","owner_cik":null,"owner_name":"Adjuvant Capital GP, L.P.; Adjuvant Capital Management, LLC; Adjuvant Global Health Technology Fund DE, L.P.; Adjuvant Global Health Technology Fund, L.P.","owner_display_name":"Adjuvant Capital GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":166666.0,"shares_display":"166,666","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":2499990.0,"total_display":"2,499,990.00","total_whole":"2,499,990","shares_owned_after":2210735.0,"shares_owned_after_display":"2,210,735","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-29","filed_date":"2022-06-24","scope":"insider"},{"id":6973815,"accession":"0000899243-22-012990","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-22-012990","line_url":"/filing/0000899243-22-012990#line-5","is_derivative":false,"issuer_cik":"0001783165","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001783165","owner_cik":null,"owner_name":"Adjuvant Global Health Technology Fund DE, L.P.; Adjuvant Global Health Technology Fund, L.P.","owner_display_name":"Adjuvant Global Health Technology Fund DE, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":166666.0,"shares_display":"166,666","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":2499990.0,"total_display":"2,499,990.00","total_whole":"2,499,990","shares_owned_after":2210735.0,"shares_owned_after_display":"2,210,735","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-03-29","filed_date":"2022-03-31","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001880438","name":"AN2 Therapeutics, Inc.","url":"/issuer/0001880438","role":"Ten percent owner","n_filings":9,"first_seen":"2022-03-31","last_seen":"2024-01-18"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001783165","retrieved_at":"2026-08-22T18:41:18+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}